Ultimovacs ASA
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 25
- Market Cap
- -
- Website
- http://www.ultimovacs.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy
- Conditions
- Prostate Cancer
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 12
- Registration Number
- NCT04701021
- Locations
- 🇳🇴
Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 156
- Registration Number
- NCT04382664
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of California Irvine Health, Orange, California, United States
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 30
- Registration Number
- NCT03538314
- Locations
- 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇺🇸University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 12
- Registration Number
- NCT02275416
- Locations
- 🇳🇴
Oslo University Hospital, Radiumhospitalet, Oslo, Norway
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 18
- Registration Number
- NCT01789099
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
- Prev
- 1
- 2
- Next
News
Ultimovacs ASA Provides Update on Clinical Trials and Financial Strategy
Ultimovacs ASA reported active enrollment in the DVO trial for BRCA-negative ovarian cancer, with results expected in the first half of 2025.
Pembrolizumab Approved for Mesothelioma; Patritumab Deruxtecan Shows Promise in NSCLC
FDA has expanded the approval of pembrolizumab (Keytruda) in combination with pemetrexed and cisplatin for previously untreated advanced/metastatic malignant pleural mesothelioma.